Clinical Scorecard: Advancements in Imaging and Management of Unknown Primary Head and Neck Squamous Cell Carcinoma: A Multidisciplinary Perspective

At a Glance

Key Highlights

• HNSCCUP accounts for 2–5% of all head and neck cancers and requires precise primary tumour detection to tailor treatment and improve outcomes.
• Multiparametric MRI is the recommended first-line imaging modality, offering superior tissue characterization and detection rates around 40%.
• Minimally invasive surgical techniques like transoral robotic surgery (TORS) and transoral laser microsurgery (TLM) improve primary tumour detection, especially in HPV-positive cases.

Guideline-Based Recommendations

Diagnosis

• Perform detailed history and physical examination including flexible fibreoptic endoscopy enhanced by narrow band imaging (NBI).
• Use ultrasound-guided fine-needle aspiration cytology (USFNAC) for initial pathological confirmation of SCC in lymph nodes.
• Conduct p16 immunohistochemistry and PCR-based HPV testing on aspirates; perform EBV testing via EBER in situ hybridisation for HPV-negative cases.
• Employ multiparametric MRI from skull base to thoracic inlet as first imaging modality; contrast-enhanced CT is an alternative based on availability.
• Reserve FDG PET CT for patients with MRI-occult tumours and to detect additional disease sites; perform prior to invasive biopsies to reduce false positives.
• Use directed biopsies, tonsillectomy, and base of tongue mucosectomy when initial evaluations fail to identify the primary tumour.

Management

• Tailor treatment modalities (surgery, radiotherapy, systemic therapies) according to the anatomical tumour origin once identified.
• Apply AJCC/UICC 9th edition TNM classification incorporating HPV and EBV status and imaging-detected extranodal extension (i-ENE) for staging.
• Consider minimally invasive surgical techniques (TORS, TLM) for diagnostic and therapeutic purposes, especially in HPV-positive HNSCCUP.

Monitoring & Follow-up

• Monitor nodal involvement and extranodal extension via imaging modalities (MRI, CT) as these impact prognosis and treatment planning.
• Assess biomarker status (HPV, EBV, PD-L1) to guide personalized treatment and immunotherapy options.

Risks

• False-positive findings on FDG PET CT due to physiologic uptake or inflammation may lead to unnecessary interventions.
• Microscopic extranodal extension cannot be detected by imaging, potentially underestimating disease extent.
• Random biopsies have low diagnostic yield and are no longer recommended.

Patient & Prescribing Data

Patients with metastatic cervical lymphadenopathy and unknown primary head and neck squamous cell carcinoma.

Biomarker testing (HPV, EBV, PD-L1) on biopsy specimens informs prognosis and guides personalized systemic therapies including immunotherapy.

Clinical Best Practices

• Integrate multidisciplinary evaluation including radiology, pathology, surgery, and oncology for comprehensive diagnosis and management.
• Use narrow band imaging (NBI) during endoscopy to enhance detection of mucosal lesions.
• Perform p16 and EBV testing to localize primary tumour and apply appropriate staging classifications.
• Employ minimally invasive surgical techniques (TORS, TLM) when conventional diagnostics fail to identify the primary tumour.
• Schedule FDG PET CT prior to invasive procedures to minimize false positives from post-procedural inflammation.

References

• 1. General overview of HNSCCUP and clinical need
• 2. HPV-related oropharyngeal SCC and diagnostic techniques
• 3. Imaging recommendations and multiparametric MRI utility
• 4. Surgical biopsy techniques and detection rates
• 5. Diagnostic reliability of USFNAC
• 6. HPV and EBV testing protocols
• 7. AJCC/UICC 9th edition TNM classification updates
• 8. MRI detection rates in HNSCCUP
• 9. Imaging detection of extranodal extension and prognostic impact
• 10. Comparative effectiveness of PET CT and clinical exams